Australian Medtech EMVision Unveils Backpack-Sized Brain Scanner to Empower First Responders
July 22 2024 - 9:42PM
Business Wire
Company’s second-generation device further
miniaturises its portable brain scanner technology to tackle the
global burden of stroke
EMVision (ASX: EMV), an Australian medical device company
focused on the development and commercialisation of innovative
portable brain scanning technology, has today unveiled its First
Responder Proof of Concept device, designed for deployment via road
and air ambulances.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240723068628/en/
EMVision's First Responder device aims to
fundamentally transform stroke and traumatic brain injury outcomes
for all patients, regardless of their location, by delivering
sophisticated neurodiagnostic technology directly to the point of
care (Photo: Business Wire)
The backpack-sized scanner weighs less than 25 lbs and will
enable paramedics to scan and send images to stroke experts from
the site of a suspected stroke. Globally, one in four people over
age 25 will have a stroke in their lifetime and EMVision’s
technology has the potential to drastically improve the speed of
diagnosis and treatment, particularly in settings where traditional
imaging modalities like CT and MRI are not readily available.
“An abiding certainty in stroke is that the fastest possible
diagnosis and treatment will result in better outcomes, such as
less disability, for patients. There is a huge unmet clinical need
for a portable, cost-effective, and easy-to-deploy device that can
distinguish whether a suspected ischaemic or haemorrhagic stroke
has occurred. We are excited by the opportunity to help
revolutionize prehospital stroke care and make a substantial
positive impact on one of the major causes of global disability,”
said Scott Kirkland, Co-Founder and CEO at EMVision.
The First Responder device leverages the underlying innovation
from EMVision’s emu™ brain scanner. The emu™ is a trolley-mounted
device, targeted for use in intensive care units, stroke and
neurology wards, and rural emergency departments, involving a
simple cap placed on the patient's head for quick scans and timely
stroke and stroke subtype assessment. It couples safe, ultra-high
frequency radio signals with powerful artificial intelligence to
produce rapid insights at the patient’s bedside.
This First Responder unit is a second-generation device with a
lighter and miniaturized design, with expanded antenna coverage
designed to offer full brain coverage in a single scan. It will now
be the subject of a series of studies and developments to ensure
its usability, reliability, and functionality to support the
regulatory approval pathway. Both devices can be operated at the
point-of-care by any healthcare professional with minimal
training.
Professor Geoffrey Donnan, co-Chair of the Australian Stroke
Alliance, emphasized the importance of the identification of
blood as a prerequisite for therapeutic decision-making in acute
stroke management. “Early results are encouraging and the
lightweight nature of the EMVision device are likely to make it
useful in the prehospital stroke environment.”
Professor Stephen Davis, co-Chair of the Australian Stroke
Alliance, said “We are looking forward to the validation of the
sensitivity and specificity for detection of blood in hyperacute
stroke patients using the EMVision device, against CT scanning, the
current gold standard in stroke management. The weight of the
device — less than 25 lbs — compares extremely favorably to a
conventional mobile CT scanner of at least 1,100 lbs.”
Dr Lisa Murphy, CEO of the Stroke Foundation, said “This
is an exciting step forward in reducing the gap that exists between
regional and metropolitan stroke care. Every Australian patient
deserves access to fast treatment and quality stroke care,
regardless of their postcode. Access to fast diagnosis and
treatment of stroke can be the difference between life or death and
recovering well or living with severe disability, so technology
like this is critical in improving outcomes for survivors of
stroke.”
The emu™️ and the First Responder device are not available for
sale nor evaluated by the FDA or other global regulators. The
devices may only be used by authorized sites in controlled clinical
investigations. Market entry for the emu™ device is planned for
next year, with the first responder device to follow.
Full details of the announcement can be found at
emvision.com.au/investors
About EMVision
EMVision Medical Devices Limited (ASX: EMV) is an innovative
Australian medical device company developing a novel approach to
looking inside the human body. Our product pipeline includes
portable, non-invasive, affordable and safe neuroimaging devices.
Our vision is to help transform and improve the timely diagnosis
and treatment of stroke and other time-sensitive medical
emergencies at the point of care. EMVision has offices in Sydney
and Brisbane www.emvisionmedical.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723068628/en/
For further information, media or investor enquiries, please
contact:
Dejan Toracki Head of Investor Relations +61 409 340 641
dtoracki@emvision.com.au
Sling & Stone Media and Communications
emvision@slingstone.com +61 2 8073 5390
Ishr Em Mv (LSE:EMV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Ishr Em Mv (LSE:EMV)
Historical Stock Chart
From Aug 2023 to Aug 2024